U072 What is Safe to Use for Routine Dermatologic Disease if Your Patient Has Been Diagnosed with Cancer?
DESCRIPTION
Designed for general dermatologists, this session tackles the critical question: how do we safely treat chronic dermatologic diseases like psoriasis, eczema, and alopecia in patients with cancer? We'll dive into the latest data on immunosuppressives, biologics, and targeted therapies, and present practical treatment algorithms. Plus, we’ll examine how cancer therapies can impact dermatologic disease. Session participants will gain confidence in managing these complex cases with data-driven, clinically relevant insights.
LEARNING OBJECTIVES
Identify the risk of cancer with systemic dermatologic therapies
Utilize systemic agents to manage dermatologic conditions in cancer patients
Recognize the effect of cancer-directed therapies on chronic dermatologic disease
SCHEDULE
4:30 PM
Introduction to Session
Brittany L Dulmage, MD, FAAD
4:35 PM
Managing psoriasis and atopic dermatitis in patients with cancer
Gowri Kabbur, MD, FAAD
4:50 PM
Managing bullous disease and utilizing immunosuppressive medications in patients with cancer
5:05 PM
Managing hair loss and acne in patients with cancer
Brittany L Dulmage, MD, FAAD
5:20 PM
Question and Answer Session
DIRECTOR
Brittany L Dulmage, MD, FAAD
SPEAKERS
Milan J Anadkat, MD, FAAD
Gowri Kabbur, MD, FAAD
DISCLOSURES
Milan J Anadkat, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Fees); Eli Lilly – Advisory Board(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); Incyte Corporation – Investigator(Grants/Research Funding); Merus B.V. – Consultant (1099 relationship)(Fees); Novartis – Investigator(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); UCB – Advisory Board(Honoraria), Investigator(Grants/Research Funding);
Brittany L Dulmage, MD, FAAD
Azitra, Inc – Investigator(Grants/Research Funding); Hoth Therapeutics – Data Safety Monitoring Board(Honoraria); Novocure – Consultant (1099 relationship)(Honoraria); Xencor – Consultant (1099 relationship)(Fees);
Gowri Kabbur, MD, FAAD
No financial relationships exist with ineligible companies.